Table S1.
Experimental design generated by Design Expert® 8.0.7.1 consisting of 17 combinations including five replicates at the central level
| Formulation | Drug/phosphatidylcholine (%, w/w, A) |
Cholesterol (%, w/v, B) |
Sonication time (minutes, C) |
|---|---|---|---|
| NLA1 | 10 | 0.1 | 3 |
| NLA2 | 20 | 0.1 | 3 |
| NLA3 | 10 | 0.3 | 3 |
| NLA4 | 20 | 0.3 | 3 |
| NLA5 | 10 | 0.2 | 2 |
| NLA6 | 20 | 0.2 | 2 |
| NLA7 | 10 | 0.2 | 4 |
| NLA8 | 20 | 0.2 | 4 |
| NLA9 | 15 | 0.1 | 2 |
| NLA10 | 15 | 0.3 | 2 |
| NLA11 | 15 | 0.1 | 4 |
| NLA12 | 15 | 0.3 | 4 |
| NLA13 | 15 | 0.2 | 3 |
| NLA14 | 15 | 0.2 | 3 |
| NLA15 | 15 | 0.2 | 3 |
| NLA16 | 15 | 0.2 | 3 |
| NLA17 | 15 | 0.2 | 3 |
Abbreviation: NLA, nanoliposomal artemisinin.